{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:30:40Z","timestamp":1790739040917,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00204-018-2284-y","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T05:35:03Z","timestamp":1535088903000},"page":"3175-3190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery"],"prefix":"10.1007","volume":"92","author":[{"given":"Anna-Karin","family":"Sj\u00f6gren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Breitholtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Ahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Forsgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone H.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"Wilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit J.","family":"Hornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"issue":"4","key":"2284_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1681\/ASN.2015010060","volume":"27","author":"M Adler","year":"2016","unstructured":"Adler M, Ramm S, Hafner M et al (2016) A quantitative approach to screen for nephrotoxic compounds in vitro. J Am Soc Nephrol 27(4):1015\u20131028. https:\/\/doi.org\/10.1681\/asn.2015010060","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"2284_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2165\/00003088-199500292-00005","volume":"29","author":"WM Awni","year":"1995","unstructured":"Awni WM, Braeckman RA, Granneman GR, Witt G, Dube LM (1995) Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600 mg in healthy volunteers. Clin Pharmacokinet 29(Suppl 2):22\u201333","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2284_CR3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2165\/00003495-199346060-00007","volume":"46","author":"JA Balfour","year":"1993","unstructured":"Balfour JA, McTavish D (1993) Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46(6):1025\u20131054. https:\/\/doi.org\/10.2165\/00003495-199346060-00007","journal-title":"Drugs"},{"issue":"3","key":"2284_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","volume":"46","author":"I Bekersky","year":"2002","unstructured":"Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ (2002) Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46(3):828\u2013833","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2284_CR5","first-page":"3032","volume":"6","author":"G Bocci","year":"2000","unstructured":"Bocci G, Danesi R, Di Paolo AD et al (2000) Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6(8):3032\u20133037","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2284_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","volume":"47","author":"RN Brogden","year":"1994","unstructured":"Brogden RN, Fitton A (1994) Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47(6):983\u20131009","journal-title":"Drugs"},{"issue":"5","key":"2284_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2165\/00003495-198836050-00003","volume":"36","author":"RN Brogden","year":"1988","unstructured":"Brogden RN, Todd PA, Sorkin EM (1988) Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36(5):540\u2013600","journal-title":"Drugs"},{"issue":"3","key":"2284_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.taap.2008.09.018","volume":"233","author":"CDA Brown","year":"2008","unstructured":"Brown CDA, Sayer R, Windass AS et al (2008) Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233(3):428\u2013438. https:\/\/doi.org\/10.1016\/j.taap.2008.09.018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"2284_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1021\/acs.molpharmaceut.5b00821","volume":"13","author":"P Caetano-Pinto","year":"2016","unstructured":"Caetano-Pinto P, Janssen MJ, Gijzen L, Verscheijden L, Wilmer MJG, Masereeuw R (2016) Fluorescence-based transport assays revisited in a human renal proximal tubule cell line. Mol Pharm 13(3):933\u2013944. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00821","journal-title":"Mol Pharm"},{"issue":"2","key":"2284_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-3956(79)90020-7","volume":"15","author":"IC Campbell","year":"1979","unstructured":"Campbell IC, Shiling DJ, Lipper S, Slater S, Murphy DL (1979) A biochemical measure of monoamine oxidase type A and B inhibitor effects in man. J Psychiatr Res 15(2):77\u201384","journal-title":"J Psychiatr Res"},{"issue":"5","key":"2284_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00003495-198938050-00003","volume":"38","author":"DM Campoli-Richards","year":"1989","unstructured":"Campoli-Richards DM, Chaplin S, Sayce RH, Goa KL (1989) Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 38(5):703\u2013756","journal-title":"Drugs"},{"issue":"5","key":"2284_CR12","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1128\/AAC.46.5.1614-1616.2002","volume":"46","author":"N Castro","year":"2002","unstructured":"Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J (2002) Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother 46(5):1614\u20131616","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"2284_CR13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","volume":"63","author":"T Chapman","year":"2003","unstructured":"Chapman T, McGavin J, Noble S (2003) Tenofovir disoproxil fumarate. Drugs 63(15):1597\u20131608","journal-title":"Drugs"},{"key":"2284_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ncpneph0076","volume":"2","author":"D Choudhury","year":"2006","unstructured":"Choudhury D, Ahmed Z (2006) Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2:80. https:\/\/doi.org\/10.1038\/ncpneph0076","journal-title":"Nat Clin Pract Nephrol"},{"issue":"6","key":"2284_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","volume":"167","author":"G Ciarimboli","year":"2005","unstructured":"Ciarimboli G, Ludwig T, Lang D et al (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167(6):1477\u20131484. https:\/\/doi.org\/10.1016\/S0002-9440(10)61234-5","journal-title":"Am J Pathol"},{"issue":"3","key":"2284_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/mol.56.3.570","volume":"56","author":"T Cihlar","year":"1999","unstructured":"Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH (1999) The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56(3):570\u2013580. https:\/\/doi.org\/10.1124\/mol.56.3.570","journal-title":"Mol Pharmacol"},{"key":"2284_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook D, Brown D, Alexander R et al (2014) Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:419. https:\/\/doi.org\/10.1038\/nrd4309","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2284_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/BF00994018","volume":"20","author":"C Cortes","year":"1995","unstructured":"Cortes C, Vapnik V (1995) Support-vector networks. Mach Learn 20(3):273\u2013297. https:\/\/doi.org\/10.1007\/BF00994018","journal-title":"Mach Learn"},{"issue":"6","key":"2284_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cpt1974156588","volume":"15","author":"RE Cutler","year":"1974","unstructured":"Cutler RE, Forrey AW, Christopher TG, Kimpel BM (1974) Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 15(6):588\u2013596","journal-title":"Clin Pharmacol Ther"},{"key":"2284_CR20","unstructured":"DailyMed (2017) National Library of Medicine, National Institutes of Health, Health and Human Services, Bethesda, MD, USA. https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm . Accessed March 2017"},{"issue":"20","key":"2284_CR21","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","volume":"63","author":"T Dando","year":"2003","unstructured":"Dando T, Plosker G (2003) Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 63(20):2215\u20132234","journal-title":"Drugs"},{"issue":"6","key":"2284_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.drudis.2013.10.023","volume":"19","author":"J Davies","year":"2014","unstructured":"Davies J (2014) Engineered renal tissue as a potential platform for pharmacokinetic and nephrotoxicity testing. Drug Discov Today 19(6):725\u2013729. https:\/\/doi.org\/10.1016\/j.drudis.2013.10.023","journal-title":"Drug Discov Today"},{"issue":"Suppl 1","key":"2284_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4137\/BMI.S20056","volume":"10","author":"JA Davies","year":"2015","unstructured":"Davies JA (2015) Self-organized kidney rudiments: prospects for better in vitro nephrotoxicity assays. Biomark Insights 10(Suppl 1):117\u2013123. https:\/\/doi.org\/10.4137\/BMI.S20056","journal-title":"Biomark Insights"},{"issue":"6","key":"2284_CR24","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2006010017","volume":"17","author":"P Devarajan","year":"2006","unstructured":"Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503\u20131520. https:\/\/doi.org\/10.1681\/asn.2006010017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2284_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF00558247","volume":"35","author":"J Douchamps","year":"1988","unstructured":"Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35(5):515\u2013520","journal-title":"Eur J Clin Pharmacol"},{"issue":"17","key":"2284_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.drudis.2007.07.013","volume":"12","author":"JA Dykens","year":"2007","unstructured":"Dykens JA, Will Y (2007) The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 12(17):777\u2013785. https:\/\/doi.org\/10.1016\/j.drudis.2007.07.013","journal-title":"Drug Discov Today"},{"issue":"1","key":"2284_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/jac\/33.1.111","volume":"33","author":"R Echols","year":"1994","unstructured":"Echols R, Weinstein MP, O\u2019Keeffe B, Shah A, Heller AH (1994) Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. J Antimicrob Chemother 33(1):111\u2013118","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2284_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/17425255.2014.876990","volume":"10","author":"P Fisel","year":"2014","unstructured":"Fisel P, Renner O, Nies AT, Schwab M, Schaeffeler E (2014) Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. Exp Opinion Drug Metab Toxicol 10(3):395\u2013408. https:\/\/doi.org\/10.1517\/17425255.2014.876990","journal-title":"Exp Opinion Drug Metab Toxicol"},{"issue":"3","key":"2284_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2165\/00003495-198733030-00002","volume":"33","author":"KL Goa","year":"1987","unstructured":"Goa KL, Campoli-Richards DM (1987) Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33(3):242\u2013258","journal-title":"Drugs"},{"issue":"6","key":"2284_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2165\/00003495-199753060-00010","volume":"53","author":"KL Goa","year":"1997","unstructured":"Goa KL, Haria M, Wilde MI (1997) Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. Drugs 53(6):1081\u20131105","journal-title":"Drugs"},{"issue":"4","key":"2284_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/bdd.2510130404","volume":"13","author":"A Grahnen","year":"1992","unstructured":"Grahnen A, Lonnebo A, Beck O, Eckernas SA, Dahlstrom B, Lindstrom B (1992) Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm Drug Dispos 13(4):255\u2013262","journal-title":"Biopharm Drug Dispos"},{"key":"2284_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2121-14-55","volume":"14","author":"AH Heussner","year":"2013","unstructured":"Heussner AH, Dietrich DR (2013) Primary porcine proximal tubular cells as an alternative to human primary renal cells in vitro: an initial characterization. BMC Cell Biol 14:55\u201355. https:\/\/doi.org\/10.1186\/1471-2121-14-55","journal-title":"BMC Cell Biol"},{"issue":"5","key":"2284_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/clpt.1981.91","volume":"29","author":"KJ Himmelstein","year":"1981","unstructured":"Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther 29(5):658\u2013664","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2284_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4155\/fmc.14.15","volume":"6","author":"JJ Hornberg","year":"2014","unstructured":"Hornberg JJ, Mow T (2014) How can we discover safer drugs? Fut Med Chem 6(5):481\u2013483. https:\/\/doi.org\/10.4155\/fmc.14.15","journal-title":"Fut Med Chem"},{"issue":"8","key":"2284_CR35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.drudis.2013.12.009","volume":"19","author":"JJ Hornberg","year":"2014","unstructured":"Hornberg JJ, Laursen M, Brenden N et al (2014a) Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies. Drug Discov Today 19(8):1137\u20131144. https:\/\/doi.org\/10.1016\/j.drudis.2013.12.009","journal-title":"Drug Discov Today"},{"issue":"8","key":"2284_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.drudis.2013.12.008","volume":"19","author":"JJ Hornberg","year":"2014","unstructured":"Hornberg JJ, Laursen M, Brenden N et al (2014b) Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. Drug Discov Today 19(8):1131\u20131136. https:\/\/doi.org\/10.1016\/j.drudis.2013.12.008","journal-title":"Drug Discov Today"},{"issue":"1","key":"2284_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.yexcr.2014.02.011","volume":"323","author":"J Jansen","year":"2014","unstructured":"Jansen J, Schophuizen CMS, Wilmer MJ et al (2014) A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. Exp Cell Res 323(1):87\u201399. https:\/\/doi.org\/10.1016\/j.yexcr.2014.02.011","journal-title":"Exp Cell Res"},{"issue":"6","key":"2284_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00424-012-1163-2","volume":"464","author":"SE Jenkinson","year":"2012","unstructured":"Jenkinson SE, Chung GW, van Loon E, Bakar NS, Dalzell AM, Brown CDA (2012) The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pfl\u00fcgers Arch Eur J Physiol 464(6):601\u2013611. https:\/\/doi.org\/10.1007\/s00424-012-1163-2","journal-title":"Pfl\u00fcgers Arch Eur J Physiol"},{"key":"2284_CR39","doi-asserted-by":"publisher","unstructured":"Kandasamy K, Chuah JKC, Su R et al (2015) Prediction of drug-induced nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells and machine learning methods. Sci Rep 5:12337 https:\/\/doi.org\/10.1038\/srep12337 . https:\/\/www.nature.com\/articles\/srep12337#supplementary-information","DOI":"10.1038\/srep12337"},{"issue":"1","key":"2284_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","volume":"67","author":"GM Keating","year":"2007","unstructured":"Keating GM, Croom KF (2007) Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67(1):121\u2013153","journal-title":"Drugs"},{"issue":"2","key":"2284_CR41","doi-asserted-by":"publisher","first-page":"F279","DOI":"10.1152\/ajprenal.1990.259.2.F279","volume":"259","author":"PS Kellerman","year":"1990","unstructured":"Kellerman PS, Clark RA, Hoilien CA, Linas SL, Molitoris BA (1990) Role of microfilaments in maintenance of proximal tubule structural and functional integrity. Am J Physiol Renal Physiol 259(2):F279\u2013F285. https:\/\/doi.org\/10.1152\/ajprenal.1990.259.2.F279","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"2284_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/00007691-200012000-00004","volume":"22","author":"R Kitzes-Cohen","year":"2000","unstructured":"Kitzes-Cohen R, Farin D, Piva G et al (2000) Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 22(6):661\u2013667","journal-title":"Ther Drug Monit"},{"key":"2284_CR43","volume-title":"Casarett and Doull\u2019s essentials of toxicology","author":"CD Klaassen","year":"2010","unstructured":"Klaassen CD, Watkins JB (2010) Casarett and Doull\u2019s essentials of toxicology, 2\u00a0edn. McGraw-Hill Medical, New York","edition":"2"},{"key":"2284_CR44","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/labinvest.2011.48","volume":"91","author":"JJ Kohler","year":"2011","unstructured":"Kohler JJ, Hosseini SH, Green E et al (2011) Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transporters. Lab Invest 91:852. https:\/\/doi.org\/10.1038\/labinvest.2011.48","journal-title":"Lab Invest"},{"key":"2284_CR45","doi-asserted-by":"publisher","unstructured":"Kohonen P, Parkkinen JA, Willighagen EL et al (2017) A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury. Nat Commun 8:15932 https:\/\/doi.org\/10.1038\/ncomms15932 . https:\/\/www.nature.com\/articles\/ncomms15932#supplementary-information","DOI":"10.1038\/ncomms15932"},{"issue":"6","key":"2284_CR46","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/j.1875-9114.1998.tb03142.x","volume":"18","author":"JM Kovarik","year":"1998","unstructured":"Kovarik JM, Purba HS, Pongowski M, Gerbeau C, Humbert H, Mueller EA (1998) Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. Pharmacotherapy 18(6):1230\u20131236","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2284_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/BF00686020","volume":"33","author":"V Kurowski","year":"1993","unstructured":"Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33(1):36\u201342","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2284_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tox.2006.08.035","volume":"228","author":"LH Lash","year":"2006","unstructured":"Lash LH, Putt DA, Cai H (2006) Membrane transport function in primary cultures of human proximal tubular cells. Toxicology 228(2):200\u2013218. https:\/\/doi.org\/10.1016\/j.tox.2006.08.035","journal-title":"Toxicology"},{"issue":"5","key":"2284_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1039\/c3tx50042j","volume":"2","author":"Y Li","year":"2013","unstructured":"Li Y, Oo ZY, Chang SY et al (2013) An in vitro method for the prediction of renal proximal tubular toxicity in humans. Toxicol Res 2(5):352\u2013365. https:\/\/doi.org\/10.1039\/C3TX50042J","journal-title":"Toxicol Res"},{"issue":"7","key":"2284_CR50","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1021\/mp400637s","volume":"11","author":"Y Li","year":"2014","unstructured":"Li Y, Kandasamy K, Chuah JK et al (2014) Identification of nephrotoxic compounds with embryonic stem-cell-derived human renal proximal tubular-like cells. Mol Pharm 11(7):1982\u20131990. https:\/\/doi.org\/10.1021\/mp400637s","journal-title":"Mol Pharm"},{"issue":"1","key":"2284_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/toxsci\/kfr339","volume":"126","author":"Z Lin","year":"2012","unstructured":"Lin Z, Will Y (2012) Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol Sci 126(1):114\u2013127. https:\/\/doi.org\/10.1093\/toxsci\/kfr339","journal-title":"Toxicol Sci"},{"issue":"4","key":"2284_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00003088-199936040-00003","volume":"36","author":"I Mahmood","year":"1999","unstructured":"Mahmood I, Sahajwalla C (1999) Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36(4):277\u2013287. https:\/\/doi.org\/10.2165\/00003088-199936040-00003","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"2284_CR53","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jps.2600761220","volume":"76","author":"A McBurney","year":"1987","unstructured":"McBurney A, Farrow PR, Ward JW (1987) Effects of formulation on the pharmacokinetics of orally administered pinacidil in humans. J Pharm Sci 76(12):940\u2013941","journal-title":"J Pharm Sci"},{"issue":"8","key":"2284_CR54","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2165\/00003495-200666080-00011","volume":"66","author":"PL McCormack","year":"2006","unstructured":"McCormack PL, Plosker GL (2006) Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents. Drugs 66(8):1151\u20131168","journal-title":"Drugs"},{"key":"2284_CR55","unstructured":"MHRA Medicines and Healthcare products Regulatory Agency (2017) Summaries of product characteristics, Dipyridamole 100 mg Tablets. http:\/\/www.mhra.gov.uk\/spc-pil\/index.htm . Accessed March 2017"},{"key":"2284_CR56","unstructured":"Micromedex 2.0 Truven Health Analytics (2017) Greenwood Village, Colorado, USA. http:\/\/www.micromedexsolutions.com . Accessed 15th March 2017"},{"key":"2284_CR57","doi-asserted-by":"publisher","unstructured":"Morgan P, Brown DG, Lennard S, et al (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov 17:167. https:\/\/doi.org\/10.1038\/nrd.2017.244 . https:\/\/www.nature.com\/articles\/nrd.2017.244#supplementary-information","DOI":"10.1038\/nrd.2017.244"},{"issue":"4","key":"2284_CR58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2165\/00003495-198223040-00002","volume":"23","author":"PA Morley","year":"1982","unstructured":"Morley PA, Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Zomepirac: a review of its pharmacological properties and analgesic efficacy. Drugs 23(4):250\u2013275","journal-title":"Drugs"},{"issue":"2","key":"2284_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0041-008X(71)90041-X","volume":"20","author":"GF Moss","year":"1971","unstructured":"Moss GF, Jones KM, Ritchie JT, Cox JS (1971) Plasma levels and urinary excretion of disodium cromoglycate afer inhalation by human volunteers. Toxicol Appl Pharmacol 20(2):147\u2013156","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"2284_CR60","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ki.2012.442","volume":"83","author":"K Narayanan","year":"2013","unstructured":"Narayanan K, Schumacher KM, Tasnim F et al (2013) Human embryonic stem cells differentiate into functional renal proximal tubular\u2013like cells. Kidney Int 83(4):593\u2013603. https:\/\/doi.org\/10.1038\/ki.2012.442","journal-title":"Kidney Int"},{"issue":"6","key":"2284_CR61","first-page":"743","volume":"78","author":"CA Naughton","year":"2008","unstructured":"Naughton CA (2008) Drug-induced nephrotoxicity. Am Fam Physician 78(6):743\u2013750","journal-title":"Am Fam Physician"},{"issue":"2","key":"2284_CR62","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1208\/s12248-016-9871-8","volume":"18","author":"TT Nieskens","year":"2016","unstructured":"Nieskens TT, Peters JG, Schreurs MJ et al (2016) A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity. AAPS J 18(2):465\u2013475. https:\/\/doi.org\/10.1208\/s12248-016-9871-8","journal-title":"AAPS J"},{"issue":"5","key":"2284_CR63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1124\/dmd.117.079384","volume":"46","author":"TTG Nieskens","year":"2018","unstructured":"Nieskens TTG, Peters JGP, Dabaghie D et al (2018) Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity. Drug Metab Dispos 46(5):592\u2013599. https:\/\/doi.org\/10.1124\/dmd.117.079384","journal-title":"Drug Metab Dispos"},{"key":"2284_CR64","doi-asserted-by":"publisher","first-page":"111130","DOI":"10.1007\/978-3-642-00663-0_5","volume":"196","author":"TD Nolin","year":"2010","unstructured":"Nolin TD, Himmelfarb J (2010) Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol 196:111\u2013130. https:\/\/doi.org\/10.1007\/978-3-642-00663-0_5","journal-title":"Handb Exp Pharmacol"},{"issue":"9","key":"2284_CR65","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00204-006-0091-3","volume":"80","author":"PJ O\u2019Brien","year":"2006","unstructured":"O\u2019Brien PJ, Irwin W, Diaz D et al (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80(9):580\u2013604. https:\/\/doi.org\/10.1007\/s00204-006-0091-3","journal-title":"Arch Toxicol"},{"issue":"1","key":"2284_CR66","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2165\/00003495-199346010-00007","volume":"46","author":"KJ Palmer","year":"1993","unstructured":"Palmer KJ, Brogden RN (1993) Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46(1):92\u2013125","journal-title":"Drugs"},{"issue":"3","key":"2284_CR67","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2165\/00003495-199345030-00009","volume":"45","author":"KJ Palmer","year":"1993","unstructured":"Palmer KJ, Holliday SM, Brogden RN (1993) Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45(3):430\u2013475","journal-title":"Drugs"},{"key":"2284_CR68","first-page":"28252830","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B (2011) Scikit-learn: machine learning in python. J Mach Learn Res 12:2825\u20132830","journal-title":"J Mach Learn Res"},{"issue":"5","key":"2284_CR69","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2165\/00003495-199652050-00009","volume":"52","author":"CM Perry","year":"1996","unstructured":"Perry CM, Faulds D (1996) Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52(5):754\u2013772","journal-title":"Drugs"},{"issue":"3","key":"2284_CR70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.vascn.2013.08.001","volume":"68","author":"M Persson","year":"2013","unstructured":"Persson M, L\u00f8ye AF, Mow T, Hornberg JJ (2013) A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 68(3):302\u2013313. https:\/\/doi.org\/10.1016\/j.vascn.2013.08.001","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"2284_CR71","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","volume":"58","author":"GL Plosker","year":"1999","unstructured":"Plosker GL, Noble S (1999) Indinavir: a review of its use in the management of HIV infection. Drugs 58(6):1165\u20131203","journal-title":"Drugs"},{"issue":"2","key":"2284_CR72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/toxsci\/kft005","volume":"132","author":"A Pointon","year":"2013","unstructured":"Pointon A, Abi-Gerges N, Cross MJ, Sidaway JE (2013) Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol Sci 132(2):317\u2013326. https:\/\/doi.org\/10.1093\/toxsci\/kft005","journal-title":"Toxicol Sci"},{"key":"2284_CR73","unstructured":"R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing"},{"issue":"7\u20138","key":"2284_CR74","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1023\/A:1009935116877","volume":"15","author":"R Regenthal","year":"1999","unstructured":"Regenthal R, Krueger M, Koeppel C, Preiss R (1999) Drug levels: therapeutic and toxic serum\/plasma concentrations of common drugs. J Clin Monit Comput 15(7\u20138):529\u2013544","journal-title":"J Clin Monit Comput"},{"issue":"12","key":"2284_CR75","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2016","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D (2016) Dose\u2013response analysis using R. PLOS One 10(12):e0146021. https:\/\/doi.org\/10.1371\/journal.pone.0146021","journal-title":"PLOS One"},{"issue":"11","key":"2284_CR76","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1177\/106002809603001108","volume":"30","author":"ML Santeiro","year":"1996","unstructured":"Santeiro ML, Stromquist C, Wyble L (1996) Phenoxybenzamine placental transfer during the third trimester. Ann Pharmacother 30(11):1249\u20131251. https:\/\/doi.org\/10.1177\/106002809603001108","journal-title":"Ann Pharmacother"},{"key":"2284_CR77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.actbio.2014.12.002","volume":"14","author":"CM Schophuizen","year":"2015","unstructured":"Schophuizen CM, De Napoli IE, Jansen J et al (2015) Development of a living membrane comprising a functional human renal proximal tubule cell monolayer on polyethersulfone polymeric membrane. Acta Biomater 14:22\u201332. https:\/\/doi.org\/10.1016\/j.actbio.2014.12.002","journal-title":"Acta Biomater"},{"issue":"4","key":"2284_CR78","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/cc11441","volume":"16","author":"M Schulz","year":"2012","unstructured":"Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A (2012) Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 16(4):R136. https:\/\/doi.org\/10.1186\/cc11441","journal-title":"Crit Care"},{"issue":"8","key":"2284_CR79","first-page":"462","volume":"33","author":"C Seitz","year":"1995","unstructured":"Seitz C, Garcia P, Arancibia A (1995) Influence of ethanol ingestion on tetracycline kinetics. Int J Clin Pharmacol Ther 33(8):462\u2013464","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"2284_CR80","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2165\/00003495-199651060-00009","volume":"51","author":"CM Spencer","year":"1996","unstructured":"Spencer CM, Barradell LB (1996) Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 51(6):982\u20131018","journal-title":"Drugs"},{"issue":"1","key":"2284_CR81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0091270002042001006","volume":"42","author":"RE Stevens","year":"2002","unstructured":"Stevens RE, Konsil J, Verrill SS et al (2002) Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J Clin Pharmacol 42(1):52\u201360","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"2284_CR82","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1007\/s00204-015-1638-y","volume":"90","author":"R Su","year":"2016","unstructured":"Su R, Xiong S, Zink D, Loo L-H (2016) High-throughput imaging-based nephrotoxicity prediction for xenobiotics with diverse chemical structures. Arch Toxicol 90(11):2793\u20132808. https:\/\/doi.org\/10.1007\/s00204-015-1638-y","journal-title":"Arch Toxicol"},{"issue":"7","key":"2284_CR83","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1021\/mp400720w","volume":"11","author":"HY Tiong","year":"2014","unstructured":"Tiong HY, Huang P, Xiong S, Li Y, Vathsala A, Zink D (2014) Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm 11(7):1933\u20131948. https:\/\/doi.org\/10.1021\/mp400720w","journal-title":"Mol Pharm"},{"issue":"9","key":"2284_CR84","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1093\/cid\/cir184","volume":"52","author":"J Ingen van","year":"2011","unstructured":"van Ingen J, Aarnoutse RE, Donald PR et al (2011) Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52(9):e194\u2013e199. https:\/\/doi.org\/10.1093\/cid\/cir184","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2284_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","volume":"48","author":"AJ Wagstaff","year":"1994","unstructured":"Wagstaff AJ, Bryson HM (1994) Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48(2):199\u2013226","journal-title":"Drugs"},{"issue":"4","key":"2284_CR86","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00003495-200363040-00009","volume":"63","author":"K Wellington","year":"2003","unstructured":"Wellington K, Goa KL (2003) Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 63(4):417\u2013437","journal-title":"Drugs"},{"issue":"2","key":"2284_CR87","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00441-009-0882-y","volume":"339","author":"MJ Wilmer","year":"2010","unstructured":"Wilmer MJ, Saleem MA, Masereeuw R et al (2010) Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 339(2):449\u2013457. https:\/\/doi.org\/10.1007\/s00441-009-0882-y","journal-title":"Cell Tissue Res"},{"issue":"1","key":"2284_CR88","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/toxsci\/kfn109","volume":"105","author":"JJ Xu","year":"2008","unstructured":"Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105(1):97\u2013105. https:\/\/doi.org\/10.1093\/toxsci\/kfn109","journal-title":"Toxicol Sci"},{"issue":"1","key":"2284_CR89","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.abb.2009.02.007","volume":"485","author":"M Yabuki","year":"2009","unstructured":"Yabuki M, Inazu M, Yamada T, Tajima H, Matsumiya T (2009) Molecular and functional characterization of choline transporter in rat renal tubule epithelial NRK-52E cells. Arch Biochem Biophys 485(1):88\u201396. https:\/\/doi.org\/10.1016\/j.abb.2009.02.007","journal-title":"Arch Biochem Biophys"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-018-2284-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-018-2284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-018-2284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:13:24Z","timestamp":1720538004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-018-2284-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2284"],"URL":"https:\/\/doi.org\/10.1007\/s00204-018-2284-y","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,24]]},"assertion":[{"value":"9 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJ Wilmer is an employee of Radboud University who holds a patent on ciPTEC. All other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}